ClinicalTrials.gg
TerminatedNCT04240886AEGISUpdated Sep 16, 2025Results posted

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds

A Phase 2 interventional study of fosmanogepix in Invasive Fungal Infections, sponsored by Basilea Pharmaceutica. Terminated at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Basilea Pharmaceutica · Phase 2, Interventional, and Treatment

Why this study was terminated
The Sponsor made a strategic decision to terminate the study, in order to prioritize a randomized comparative Phase 3 trial in the same indication. This decision was not based on any safety concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Invasive Fungal Infections with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Invasive Fungal Infections · United States.

Enrollment
15th of 19
21 · median 88
Started
2020
with 1 other
Phase 2
3 of 24
1 open now
Registered
19th of 24
by date
Lead sponsor
2 of 24
Basilea Pharmaceutica

Among the 24 studies in Invasive Fungal Infections with a site in United States, this one is the 15th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 2, and was the 19th registered.

Invasive Fungal Infections

136 studies on the registry are indexed under Invasive Fungal Infections; 33 are open to participants now.

Browse Invasive Fungal Infections studies →

Open to participants now

2 of the 24 studies in Invasive Fungal Infections with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Invasive Fungal Infections studies recruiting now, 12 (60%) set no upper age limit and 5 (25%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Invasive Fungal Infections with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).

03

Conditions studied

  • Invasive Fungal Infections

Keywords

  • APX001
  • APX001A
  • fosmanogepix
  • manogepix
  • aspergillus
  • aspergillosis
  • covid
  • covid19
  • mold
  • mould
  • pulmonary aspergillosis
  • pulmonary aspergillus
  • galactomannan
  • Karius
  • SARS-CoV-2
  • fusarium
  • mucorales
  • mucor
  • rhizopus
  • scedosporium
  • fungal disease
  • invasive fungal disease
  • EORTC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, 18 years or older.
  • Patients with proven or probable IMI caused by Aspergillus spp. Patients who present with IMI due to other filamentous fungi (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi such as Mucor spp. or Rhizopus spp.) may also be enrolled.
  • Have limited or no treatment options due to documented or anticipated resistance, , intolerance, or lack of clinical response to SOC antifungal therapy, as advocated by the relevant regional/country treatment guidelines.
  • Patients where the Investigator considers that there is a potential advantage of using APX001 over current SOC (eg, broad spectrum of activity, emergence of IMI during antifungal prophylaxis, activity against resistant mold pathogens, IV and PO formulations, favorable DDI profile, favorable hepatic and renal safety profile, wide tissue distribution including brain), and/or where the SOC antifungal therapy carries significant risk of toxicity or treatment failure (eg, DDI risk, safety/toxicity risk, site of infection not accessible by SOC).

Exclusion criteria

Exclusion Criteria:

  • hematologic .
  • Chronic aspergillosis, aspergilloma, or allergic bronchopulmonary aspergillosis.
  • Treatment with systemic (PO, IV, or inhaled) mold active antifungal therapy for 120 hours immediately before initial dosing. Note: patients with invasive fungal infection caused by a mold with documented resistance to or lack of coverage by the prior SOC in question, may have received >120 hours prior treatment and remain eligible for the study.
  • Evidence of significant hepatic dysfunction.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Cohort A: fosmanogepix (APX001)

    Drug: fosmanogepix

  • Experimental
    Cohort B: fosmanogepix (APX001)

    Drug: fosmanogepix

Interventions

  • IV and oral fosmanogepix

    Also known as: APX001, E210

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Died After the First Dose of Study Drug Through Day 42

    Percentage of participants who died after first dose in the study through Day 42 were reported in this outcome measure. This outcome measure included all deaths from Day 1 through Day 42.

    Time frame: After first dose on Day 1 through Day 42

Secondary outcomes

  1. Percentage of Participants With Global Response Based on Data Review Committee (DRC) Assessment at End of Study Drug Treatment (EOST)

    Global response was classified as treatment success (complete or partial response \[CR or PR\]) or treatment failure (stable response \[SR\], progression of fungal disease \[PD\], or death) as determined by DRC. CR: survival within prespecified period of observation (PPOB), resolution of all attributable (att) symptoms and signs of disease and radiological (rad) abnormalities, and mycological (myco) evidence of eradication of disease. PR: survival within POB, improvement in att symptoms and signs of disease and rad abnormalities, and evidence of clearance of cultures or reduction of fungal burden. SR: survival within PPOB, minor or no improvement in fungal disease but no evidence of progression based on composite of clinical, rad and myco criteria, PD or death. PD: evidence of progressive fungal disease based on composite of clinical, rad and myco criteria. Death: death during PPOB, regardless of attribution. Data is presented for EOST which could have preceded Day 42 for some participants.

    Time frame: Any day from Day 1 until end of study treatment (any day up to Day 42)

  2. Percentage of Participants With Treatment Success or Treatment Failure for Global Response Based on Data Review Committee (DRC) Assessment at End of Study Drug Treatment (EOST)

    Global response was classified as treatment success (CR or PR) or treatment failure (SR, PD or death) as determined by DRC. CR: survival within prespecified POB, resolution of all attributable symptoms and signs of disease and rad abnormalities and myco evidence of eradication of disease. PR: survival within prespecified POB, improvement in attributable symptoms and signs of disease and rad abnormalities and evidence of clearance of cultures or reduction of fungal burden. SR: survival within prespecified POB, minor or no improvement in fungal disease, but no evidence of progression, based on composite of clinical, rad, and myco criteria, PD or death. PD: evidence of PD based on a composite of clinical, rad, and myco criteria. Death: death during prespecified period of evaluation, regardless of attribution. Percentage of participants with treatment success (CR, PR) and treatment failure (SR, PD, death) along with two-sided exact binomial 80% confidence interval is presented.

    Time frame: Any day from Day 1 until end of study treatment (any day up to Day 42)

  3. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were events between first dose of study drug and up to 4 weeks post last dose of study treatment that were absent before treatment or that worsened relative to pretreatment state. An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. AEs included SAEs and all non-SAEs.

    Time frame: Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days)

  4. Number of Participants With Clinically Significant Abnormality in Vital Signs

    Vital signs included body temperature, blood pressure, heart rate, respiratory rate, and oxygen saturation. Number of participants with clinically significant abnormality in vital signs as judged by investigator were reported in this outcome measure.

    Time frame: Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days)

  5. Number of Participants With Clinically Significant Abnormality in Laboratory Test Evaluations

    Clinical laboratory assessments included serum chemistry (bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, creatinine, creatine kinase), hematology (including hemoglobin, hematocrit, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes), coagulation (including Prothrombin time \[PT\]/ International normalized ratio \[INR\]), and urinalysis. Number of participants with clinically significant abnormality in any laboratory parameter as judged by investigator and reported as adverse events were presented.

    Time frame: Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days)

  6. Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Findings

    ECG parameters included PR interval, QRS interval, QT interval, QT interval corrected using the Fridericia's formula (QTcF), QT interval corrected using the Bazett's formula (QTcB), RR interval and heart rate. Number of participants with clinically significant abnormal ECG findings as judged by investigator were presented.

    Time frame: Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days)

  7. Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examinations

    Physical examination included an assessment of general appearance, skin, eyes, heart, chest, abdomen, and a neurological examination. Components of the neurological examination included cranial nerve, sensory, and motor examination; reflex and gait testing; and coordination assessment. Clinically significant changes were judged by investigator.

    Time frame: Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days)

  8. Plasma Concentrations of Fosmanogepix

    Time frame: Days 1, 2, 3, 4, 7: Pre-dose and 3 hours post-dose; Days 6, 13, 14: 3 hours post-dose, Day 15: pre-dose

07

Results

Posted May 19, 2023

Participant flow

Study was planned to be conducted in two parallel cohorts: Cohort A included participants with invasive mold infections (IMA) and an exploratory Cohort B was planned to include participants with invasive aspergillus, who had COVID-19 or Influenza A/B. The study was terminated early and no participants were enrolled in Cohort B; hence data is not reported for Cohort B in any section.

Treatment Phase
Participant flow — Treatment Phase
MilestoneAPX001 (Fosmanogepix): Cohort A
Started21
Completed11
Not completed10
Withdrew: Death4
Withdrew: Discontinuation by subject1
Withdrew: Adverse event5
Follow-up Phase
Participant flow — Follow-up Phase
MilestoneAPX001 (Fosmanogepix): Cohort A
Started17
Completed13
Not completed4
Withdrew: Withdrawal by subject1
Withdrew: Discontinuation by subject1
Withdrew: Death2

Outcome measures

PrimaryPercentage of Participants Who Died After the First Dose of Study Drug Through Day 42

Percentage of participants who died after first dose in the study through Day 42 were reported in this outcome measure. This outcome measure included all deaths from Day 1 through Day 42.

Time frame:
After first dose on Day 1 through Day 42
Reported as:
Number · Percentage of participants
Percentage of Participants Who Died After the First Dose of Study Drug Through Day 42
Percentage of participantsAPX001 (Fosmanogepix): Cohort A
Percentage of Participants Who Died After the First Dose of Study Drug Through Day 4225.0 (12.7 to 41.5)
SecondaryPercentage of Participants With Global Response Based on Data Review Committee (DRC) Assessment at End of Study Drug Treatment (EOST)

Global response was classified as treatment success (complete or partial response \[CR or PR\]) or treatment failure (stable response \[SR\], progression of fungal disease \[PD\], or death) as determined by DRC. CR: survival within prespecified period of observation (PPOB), resolution of all attributable (att) symptoms and signs of disease and radiological (rad) abnormalities, and mycological (myco) evidence of eradication of disease. PR: survival within POB, improvement in att symptoms and signs of disease and rad abnormalities, and evidence of clearance of cultures or reduction of fungal burden. SR: survival within PPOB, minor or no improvement in fungal disease but no evidence of progression based on composite of clinical, rad and myco criteria, PD or death. PD: evidence of progressive fungal disease based on composite of clinical, rad and myco criteria. Death: death during PPOB, regardless of attribution. Data is presented for EOST which could have preceded Day 42 for some participants.

Time frame:
Any day from Day 1 until end of study treatment (any day up to Day 42)
Reported as:
Number · Percentage of participants
Percentage of Participants With Global Response Based on Data Review Committee (DRC) Assessment at End of Study Drug Treatment (EOST)
Percentage of participantsAPX001 (Fosmanogepix): Cohort A
CR20.0
PR20.0
SR10.0
PD30.0
Death20.0
SecondaryPercentage of Participants With Treatment Success or Treatment Failure for Global Response Based on Data Review Committee (DRC) Assessment at End of Study Drug Treatment (EOST)

Global response was classified as treatment success (CR or PR) or treatment failure (SR, PD or death) as determined by DRC. CR: survival within prespecified POB, resolution of all attributable symptoms and signs of disease and rad abnormalities and myco evidence of eradication of disease. PR: survival within prespecified POB, improvement in attributable symptoms and signs of disease and rad abnormalities and evidence of clearance of cultures or reduction of fungal burden. SR: survival within prespecified POB, minor or no improvement in fungal disease, but no evidence of progression, based on composite of clinical, rad, and myco criteria, PD or death. PD: evidence of PD based on a composite of clinical, rad, and myco criteria. Death: death during prespecified period of evaluation, regardless of attribution. Percentage of participants with treatment success (CR, PR) and treatment failure (SR, PD, death) along with two-sided exact binomial 80% confidence interval is presented.

Time frame:
Any day from Day 1 until end of study treatment (any day up to Day 42)
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Success or Treatment Failure for Global Response Based on Data Review Committee (DRC) Assessment at End of Study Drug Treatment (EOST)
Percentage of participantsAPX001 (Fosmanogepix): Cohort A
Treatment Success40.0 (24.9 to 56.7)
Treatment Failure60.0 (43.3 to 75.1)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were events between first dose of study drug and up to 4 weeks post last dose of study treatment that were absent before treatment or that worsened relative to pretreatment state. An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. AEs included SAEs and all non-SAEs.

Time frame:
Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsAPX001 (Fosmanogepix): Cohort A
TEAEs21
SAEs13
SecondaryNumber of Participants With Clinically Significant Abnormality in Vital Signs

Vital signs included body temperature, blood pressure, heart rate, respiratory rate, and oxygen saturation. Number of participants with clinically significant abnormality in vital signs as judged by investigator were reported in this outcome measure.

Time frame:
Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormality in Vital Signs
ParticipantsAPX001 (Fosmanogepix): Cohort A
Number of Participants With Clinically Significant Abnormality in Vital Signs5
SecondaryNumber of Participants With Clinically Significant Abnormality in Laboratory Test Evaluations

Clinical laboratory assessments included serum chemistry (bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, creatinine, creatine kinase), hematology (including hemoglobin, hematocrit, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes), coagulation (including Prothrombin time \[PT\]/ International normalized ratio \[INR\]), and urinalysis. Number of participants with clinically significant abnormality in any laboratory parameter as judged by investigator and reported as adverse events were presented.

Time frame:
Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormality in Laboratory Test Evaluations
ParticipantsAPX001 (Fosmanogepix): Cohort A
Number of Participants With Clinically Significant Abnormality in Laboratory Test Evaluations12
SecondaryNumber of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Findings

ECG parameters included PR interval, QRS interval, QT interval, QT interval corrected using the Fridericia's formula (QTcF), QT interval corrected using the Bazett's formula (QTcB), RR interval and heart rate. Number of participants with clinically significant abnormal ECG findings as judged by investigator were presented.

Time frame:
Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Findings
ParticipantsAPX001 (Fosmanogepix): Cohort A
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Findings0
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examinations

Physical examination included an assessment of general appearance, skin, eyes, heart, chest, abdomen, and a neurological examination. Components of the neurological examination included cranial nerve, sensory, and motor examination; reflex and gait testing; and coordination assessment. Clinically significant changes were judged by investigator.

Time frame:
Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examinations
ParticipantsAPX001 (Fosmanogepix): Cohort A
Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examinations3
SecondaryPlasma Concentrations of Fosmanogepix
Time frame:
Days 1, 2, 3, 4, 7: Pre-dose and 3 hours post-dose; Days 6, 13, 14: 3 hours post-dose, Day 15: pre-dose
Reported as:
Geometric mean · nanogram per milliliter
Plasma Concentrations of Fosmanogepix
nanogram per milliliterAPX001 (Fosmanogepix): Cohort A
Day 1: Pre-dose0.0 ± 0.0
Day 1: 3 hrs post-dose387.4 ± 289.6
Day 2: Pre-dose20.4 ± 138.1
Day 2: 3 hrs post-dose406.4 ± 202.9
Day 3: Pre-dose8.6 ± 184.1
Day 3: 3 hrs post-dose486.7 ± 154.6
Day 4: Pre-dose2.9 ± 141.3
Day 4: 3 hrs post-dose85.2 ± 14743.4
Day 6: 3 hrs post-dose6.8 ± 1541.9
Day 7: Pre-dose9.8 ± 716.5
Day 7: 3 hrs post-dose37.9 ± 382.3
Day 13: 3 hrs post-dose96.4 ± NA
Day 14: 3 hrs post-dose706.8 ± 181.0
Day 15: Pre-dose0.5 ± NA

Adverse events

Collected over For adverse events (SAEs and non-SAEs): Day 1 up to maximum of 31 days of follow up post last dose of study treatment, where maximum treatment duration was 42 days (maximum up to 73 days); for all-cause mortality: Throughout the study (Day 1 to Day 84). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
APX001 (Fosmanogepix): Cohort A9/21 (42.9%)13/21 (61.9%)21/21 (100%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventAPX001 (Fosmanogepix): Cohort A
Febrile neutropeniaBlood and lymphatic system disorders3/21
Cardiac arrestCardiac disorders2/21
DiarrhoeaGastrointestinal disorders2/21
SepsisInfections and infestations2/21
Respiratory failureRespiratory, thoracic and mediastinal disorders2/21
ThrombocytopeniaBlood and lymphatic system disorders1/21
Ventricular tachycardiaCardiac disorders1/21
Abdominal painGastrointestinal disorders1/21
VomitingGastrointestinal disorders1/21
Sudden deathGeneral disorders1/21
Most frequent other events
Showing 10 of 138
Most frequent other events
EventAPX001 (Fosmanogepix): Cohort A
NauseaGastrointestinal disorders13/21
DiarrhoeaGastrointestinal disorders10/21
VomitingGastrointestinal disorders9/21
Oedema peripheralGeneral disorders6/21
Decreased appetiteMetabolism and nutrition disorders6/21
PyrexiaGeneral disorders5/21
Abdominal painGastrointestinal disorders4/21
ChillsGeneral disorders4/21
Aspartate aminotransferase increasedInvestigations4/21
HeadacheNervous system disorders4/21

Baseline characteristics

Safety population included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)APX001 (Fosmanogepix): Cohort A
Mean62.38 ± 11.71
Sex: Female, Male
Sex: Female, Male(Participants)APX001 (Fosmanogepix): Cohort A
Female2
Male19
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)APX001 (Fosmanogepix): Cohort A
Hispanic or Latino1
Not Hispanic or Latino19
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)APX001 (Fosmanogepix): Cohort A
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White20
More than one race0
Unknown or Not Reported1
08

Study locations

15 sites
  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
    Duarte, California 91010, United States
  • IP Address : City of Hope Investigational Drug Services (IDS)
    Duarte, California 91010, United States
  • Duke Department of Pharmacy/Investigational Drug Service (IDS)
    Durham, North Carolina 27710, United States
  • Duke Medicine Pavilion
    Durham, North Carolina 27710, United States
  • Duke University Medical Center (Duke South Clinic)
    Durham, North Carolina 27710, United States
  • Duke University Medical Center(Duke Hospital)
    Durham, North Carolina 27710, United States
  • Cliniques Universitaires de Bruxelles Hôpital Erasme - Department of Infectious Diseases
    Brussels, 1070, Belgium
  • UZ Leuven - Department of Haematology
    Leuven, 3000, Belgium
  • CHU UCL Namur - Mont- Godinne University Hospital - Intensive Care Unit
    Yvoir, 5530, Belgium
  • Klinikum Neuperlach, Klinik fur Hamatologie und Onkologie
    München, Bavaria 81737, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz III
    Mainz, 55131, Germany
  • Pharmacy
    Haifa, 3109601, Israel
  • Rambam Medical Center
    Haifa, 3109601, Israel
  • Pharmacy
    Ramat Gan, 5262160, Israel
  • Sheba Medical Center, Tel Hashomer
    Ramat Gan, 5262160, Israel
09

References and documents

Publications

  • Hodges MR, Tawadrous M, Cornely OA, Thompson GR, Slavin MA, Maertens JA, Dadwal SS, Rahav G, Hazel S, Almas M, Jakate A, Pypstra R. Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS). Clin Infect Dis. 2025 Dec 24;81(5):e302-e309. doi: 10.1093/cid/ciaf185. PubMed 40203286 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Mar 2022, 26 months.

Results were first posted in May 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2020
First posted
Jan 27, 2020
StartActual
Jan 4, 2020
Primary completionActual
Mar 29, 2022
CompletionActual
May 9, 2022
Results first posted
May 19, 2023
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04240886
Responsible party
Sponsor
First posted
Jan 27, 2020
Start date
Jan 4, 2020
Primary completion
Mar 29, 2022
Completion
May 9, 2022
Results posted
May 19, 2023
Last update
Sep 16, 2025

Study contacts

Marc Engelhardt
study director · Basilea Pharmaceutica International Ltd, Allschwil

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fosmanogepix

Start the discussion